a6ac1c4b4e
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md - Domain: health - Claims: 0, Entities: 1 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
34 lines
No EOL
1.3 KiB
Markdown
34 lines
No EOL
1.3 KiB
Markdown
# NCT04199728: GLP-1 Receptor Agonist for Opioid Use Disorder
|
|
|
|
**Type:** Clinical trial
|
|
**Phase:** 2
|
|
**Status:** Active (as of April 2026)
|
|
**Intervention:** GLP-1 receptor agonist (specific drug not specified in source)
|
|
**Target:** Opioid Use Disorder (OUD)
|
|
|
|
## Trial Context
|
|
|
|
Part of broader GLP-1 substance use disorder research program. As of April 2026, 4 OUD trials active out of 33 total SUD trials.
|
|
|
|
## Evidence Base
|
|
|
|
**Liraglutide OUD data:**
|
|
- ~40% reduction in opioid craving in small randomized double-blind placebo-controlled residential study
|
|
- Phase 2 evidence only
|
|
|
|
**Semaglutide OUD data:**
|
|
- Significantly reduced opioid overdose risk in 1-year follow-up for patients with comorbid T2D + OUD (real-world observational data)
|
|
- Cannot distinguish causal mechanism from selection effects
|
|
|
|
**Mechanism:** GLP-1 receptors in ventral tegmental area (VTA) and nucleus accumbens reduce dopamine surge from opioid exposure, attenuating reward salience.
|
|
|
|
**Critical limitation:** All human evidence from patients with comorbid metabolic disease. Efficacy for OUD without T2D/obesity comorbidity unknown and largely unstudied.
|
|
|
|
## Timeline
|
|
|
|
- **2026-04-28** — NBC News synthesis reports Phase 2 evidence for GLP-1 in OUD, no Phase 3 trials completed
|
|
|
|
## Sources
|
|
|
|
- NBC News/Pharmacy Times synthesis, April 2026
|
|
- ClinicalTrials.gov NCT04199728 |